EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m. ET.  A live audio webcast will be availab ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estim ...

EXTON, Pa., Dec. 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the Company's Board of Directors has elected Janet Haugen as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors. Janet Haugen Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Hauge ...

West Pharmaceutical Services, Inc. (WST) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 12.8% year to date against the industry's 2.8% growth. The S&P 500 Index has increased 23.4% in the same time frame.West Pharmaceutical, with a market capitalization of $22.78 billion, is a leading global manufacturer, engaged in th ...

EXTON, Pa., Oct. 29, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Pablos Verdes, California, on November 12, 2024 at 3:30 PM PST Jefferies Healthcare Conference in London, UK on Tuesday, November 19, 2024 at 1:00 PM GMT Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21, 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justi ...

Third-Quarter 2024 WST Q3 2024 Earnings 1 Third Quarter Overall Net Sales $746.9M | 0.1% Diluted Earnings Per Share: $1.85 Adjusted Diluted Earnings Per Share: $1.85 "We are pleased to report solid third quarter results. Our West team across the globe continues to execute at a high-level, motivated by our purpose of improving patient lives. A key aspect of our strategy is West's team of scientific thought leaders and technical experts who continue to drive strong partnership and close collaboration with our ...

On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the consensus of $709.62 million.The Proprietary Products Segment’s sales declined by 0.2% to $601.4 million, and the organic net sales decline was 0.5%.High-value products (components and devices) represented over 75% of segment net sal ...

West Pharmaceutical Services, Inc. (WST) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.85, which beat the Zacks Consensus Estimate of $1.51 by 22.5%. However, the bottom line decreased 14.4% year over year.The adjustments include expenses related to the amortization of acquisition-related intangible assets.GAAP EPS for the quarter was $1.85, down 13.6% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenues in DetailWest Pharmaceutical registere ...